Hematology · Medical Literature
[Editorial] Learning from a decade of progress in amyloidosis
Abstract
Improving outcomes for people with rare diseases is a major challenge, but it is possible. Amyloidosis is a heterogeneous group of rare disorders in which amyloid (misfolded protein deposits) accumulates in the tissues, causing progressive organ failure. Until recently, it was a rapidly fatal disease with few therapeutic options. However, as detailed in a Review in this issue, several new treatments have been approved since 2018, and for people with some subtypes estimated 10-year survival has increased from about 5% to 20%.
Clinical relevance
What lessons can be drawn from the past decade of therapeutic progress in amyloidosis—including advances in diagnosis, treatment approval, and survival improvement—and what challenges remain in translating these gains equitably? __SNAPSHOT__ {"studyDesign":"Editorial (opinion and synthesis piece accompanying a paired systematic Review in the same issue of The Lancet; not a primary research study or systematic review/meta-analysis)","setting":"Not reported; editorial perspective is international in scope","sampleSize":"Not applicable (editorial; no primary patient cohort)","population":"Patients with systemic amyloidosis, with emphasis on the two most common subtypes: light-chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis","intervention":"Multiple newly approved disease-modifying therapies for AL and ATTR amyloidosis since 2018, including gene-silencing agents (e.g., vutrisiran), TTR stabilizers (e.g., tafamidis), and CD38-targeting antibodies (e.g., daratumumab); advances in non-invasive diagnostics including SPECT scintigraphy and AI-assisted ECG/echocardiography interpretation","comparator":"Not applicable (editorial commentary; no formal comparator arm)","primaryOutcome":"Estimated 10-year survival in select amyloidosis subtypes (reported as increasing from approximately 5% to 20%); broader lessons for rare disease therapeutics","followUp":"Not reported; editorial references progress over a decade (approximately 2015–2026)","fundingSource":"Not reported (The Lancet editorial)"}
Key findings
The editorial reports that, for people with some amyloidosis subtypes, estimated 10-year survival has increased from approximately 5% to 20% following the approval of several new therapies since 2018—a four-fold relative improvement. No confidence intervals, p-values, hazard ratios, or NNT/NNH are reported; the survival figures are described as estimates without reference to a specific primary study or defined patient cohort, and should be interpreted accordingly. Key therapeutic advances cited include gene-silencing agents such as vutrisiran to reduce hepatic transthyretin production, and emerging gene-editing approaches for ATTR amyloidosis; daratumumab (a CD38-targeting antibody) approved by the FDA in 2021 for AL amyloidosis; and BCMA-targeting therapies under investigation. Diagnostic progress includes the non-invasive SPECT scintigraphy pathway (serum free light chains to exclude plasma cell disorder, followed by nuclear imaging) and growing interest in AI-enabled early detection via ECG and echocardiography, though biopsy remains frequently required. ATTR cardiomyopathy was reported in one study to be present in 2.5–14% of patients with heart failure with preserved ejection fraction (HFpEF), approaching 20% prevalence when features such as bilateral carpal tunnel syndrome were present, suggesting substantially greater disease burden than previously recognized. No adverse event data are reported in this editorial. All values cited reflect editorial synthesis and are not independently calculable from the abstract.
Practice implications
This editorial establishes that amyloidosis—once a rapidly fatal orphan disease—has undergone a transformative therapeutic shift over the past decade, driven by mechanistic classification (by precursor protein, affected organ, and hereditary vs. acquired status), targeted drug development, and improved non-invasive diagnostics. The findings apply most directly to AL and ATTR amyloidosis, the two most prevalent subtypes; rarer subtypes are explicitly noted as underserved by current research investment. The editorial does not establish causality between specific therapies and the survival improvement, nor does it stratify outcomes by disease stage, age, comorbidity burden, or geographic region. Key populations not adequately represented include patients in low- and middle-income countries and those outside major urban centers, where amyloidosis care infrastructure remains concentrated. The editorial explicitly cautions that progress has been uneven, with substantial access disparities, high drug costs (reported elsewhere as $250,000–$475,000 annually), and insufficient therapeutic development for rarer subtypes. Early diagnosis is emphasized as a persistent unmet need: the median time from symptom onset to AL amyloidosis diagnosis has been reported at approximately 2.7 years in other literature. Clinicians should note that the 10-year survival figure (5% to 20%) is an editorial estimate accompanying a Review article, not a meta-analytic pooled outcome; the paired Review (Merlini et al., The Lancet, 2026) should be consulted for the primary evidence base. IMPORTANT LIMITATION: Only the editorial abstract was available for this analysis; the full text was behind a paywall. The paired Review article was not analyzed. __LIMITATIONS__ 1. Study design: This is an editorial, the lowest level of evidence in the hierarchy; it presents no original data, no patient cohort, and no statistical analysis. 2. Survival estimates: The 10-year survival figures (5% to 20%) are editorial assertions without reported confidence intervals, source citations within the abstract, or specification of which subtypes, treatment eras, or patient populations are being compared. 3. Subtype heterogeneity: Amyloidosis comprises more than 30 recognized subtypes; aggregating survival across subtypes without granular reporting risks misleading clinicians about outcomes for specific patient populations. 4. Access and generalizability: The editorial itself acknowledges that amyloidosis care infrastructure remains concentrated in major cities and high-income countries, limiting generalizability. 5. Cost and access barriers: Therapies discussed carry substantial annual costs ($250,000–$475,000), representing a real-world barrier not addressed in survival analyses. 6. Diagnostic lag: Early diagnosis remains a critical challenge; survival improvements may disproportionately reflect outcomes in patients diagnosed at earlier disease stages at specialized centers. 7. Abstract-only analysis: The full editorial text and the paired Review (the primary evidentiary document) were not available for this analysis, limiting the depth and precision of this summary. __BOTTOM_LINE_CATEGORY__ confirmatory __BOTTOM_LINE__ The past decade has produced a genuine and clinically meaningful survival improvement in amyloidosis—particularly AL and ATTR subtypes—driven by targeted drug approvals since 2018 and advances in non-invasive diagnosis; estimated 10-year survival in some subtypes has risen from approximately 5% to 20%, though this figure is an editorial estimate without granular statistical support. Clinicians should prioritize early recognition (especially ATTR-CM in HFpEF, bilateral carpal tunnel syndrome, or unexplained hypertrophic cardiomyopathy) and prompt referral to specialized centers, as diagnostic delay remains the dominant modifiable barrier to improved outcomes. Access inequities, high drug costs, and underinvestment in rarer subtypes represent the critical unresolved challenges for the next decade.